Guia Lumbalgia (cambios 8 feb).FH10 - Digemid

62622. Koes BW, Scholten RJPM, Mens JMA, Bouter LM. Efficacy of non-steroidal anti-inflammatorydrugs for low back pain: a systematic review of randomised clinical trials. Ann Rheum Dis 1997;56: 214-23.3. van Tulder MW, Scholten RJPM, Koes BW, Deyo RA. Non-steroidal anti-inflammatory drugs(NSAIDs) for non-specific low back pain (Cochrane Review). In: The Cochrane Library, Issue 4,2000. Oxford: Update Software.4. van Tulder MW, Touray T, Furlan AD, Solway S, Bouter LM. Muscle relaxants for non-specificlow back pain (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester, UK: JohnWiley & Sons, Ltd.5. Amadio P, Cummings DM (1983) Evaluation of acetaminophen in the management of osteoarthiritsof the knee. Curr Ther Res, 34(1): 59-66.6. Berry H, Bloom B, Hamilton EB, Swinson DR (1982) Naproxen sodium, diflunisal, and placeboin the treatment of chronic back pain. Ann Rheum Dis, 41(2): 129-32.7. Birbara CA, Puopolo AD, Munoz DR, Sheldon EA, Mangione A, Bohidar NR, Geba GP (2003)Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor:improvement in pain and disability--a randomized, placebo-controlled, 3-month trial. J Pain, 4(6):307-15.8. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB,Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (2000) Comparison of upper gastrointestinaltoxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. NEngl J Med, 343(21): 1520-8, 2 p following 8.9. Chrubasik S, Model A, Black A, Pollak S (2003) A randomized double-blind pilot study comparingDoloteffin and Vioxx in the treatment of low back pain. Rheumatology (Oxford), 42(1): 141-8.10.Hickey RF (1982) Chronic low back pain: a comparison of diflunisal with paracetamol. N Z MedJ, 95(707): 312-4.11.Ju WD, Krupa DA, Walters DJ, Newman TL, Borenstein DG, Katz N, Group VC (2001) A placebocontrolledtrial of rofecoxib in the treatment of chronic low back pain. Pain Med, 2(3): 242-3.12.Katz N, Ju WD, Krupa DA, Sperling RS, Bozalis Rodgers D, Gertz BJ, Gimbel J, Coleman S,Fisher C, Nabizadeh S, Borenstein D (2003) Efficacy and safety of rofecoxib in patients withchronic low back pain: results from two 4-week, randomized, placebo-controlled, parallel-group,double-blind trials. Spine, 28(9): 851-8; discussion 9.13.Katz N, Rodgers DB, Krupa D, Reicin A (2004) Onset of pain relief with rofecoxib in chronic lowback pain: results of two four-week, randomized, placebo-controlled trials. Curr Med Res Opin,20(5): 651-8.14.Pallay R, Seger W, Adler J, Ettlinger R, Quaidoo E, Lipetz R, O'Brien K, Mucciola L, Skalky C,Petruschke R, Bohidar N, Geba G (2004) Etoricoxib reduced pain and disability and improvedquality of life in patients with chronic low back pain: a 3 month, randomized, controlled trial. ScandJ Rheumatol, 33(4): 257-66.15.Postacchini F, Facchini M, Palieri P (1988) Efficacy of various forms of conservative treatmentin low back pain: a comparative study. Neurol Orthop, 6: 113-6.16.Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G,Agrawal NM, Stenson WF, Burr AM, Zhao WW, Kent JD, Lefkowith JB, Verburg KM, Geis GS(2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs forosteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. CelecoxibLong-term Arthritis Safety Study. Jama, 284(10): 1247-55.17.Topol EJ (2004) Failing the Public Health -- Rofecoxib, Merck, and the FDA. N Engl J Med.18.Towheed TE, Judd MJ, Hochberg MC, Wells G (2003) Acetaminophen for osteoarthritis. CochraneDatabase Syst Rev, (2): CD004257.19.van Tulder MW, Koes BW, Bouter LM (1997) Conservative treatment of acute and chronicnonspecific low back pain. A systematic review of randomized controlled trials of the most commoninterventions. Spine, 22(18): 2128-56.